Piramal Pharma Jumps 10%+ as 70+ Global Regulatory Approvals Signal Pipeline Strength

A surge in multi-geography approvals spanning likely CDMO and branded generics segments drives strong investor sentiment, though revenue conversion timelines and approval breakdown details remain unconfirmed.

ndtv-profit-business · 6/28/2026, 10:30:36 AM · Ask about this →